RxDoctor Payments Data

Jennifer Brown, APRN

Psychiatric/Mental Health · Lees Summit, MONPI 1548659675

Payments from drug & device makers

$1,596in general payments, 2019–2025

Across 116 payments — averaging $13.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$261
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$236
  • Sunovion Pharmaceuticals Inc.$210
  • Otsuka America Pharmaceutical, Inc.$200
  • Alkermes, Inc.$162
  • Lundbeck LLC$114
  • plus $413 from 10 others

What the payments were for

  • Food & beverage$1,54997%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,596 in reported general payments places this provider in the 65th percentile of 565 psychiatric/mental health providers in Missouri.

See all psychiatric/mental health providers in Missouri

Medicare billing

Part B allowed, 2024
$28,943
Medicare patients
114
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine20$113,629
RexultiBrexpiprazole28$47,447
Risperdal ConstaRisperidone Microspheres23$26,483
VraylarCariprazine Hcl18$25,050
FanaptIloperidone14$24,741
SpravatoEsketamine Hcl18$23,239
TrintellixVortioxetine Hydrobromide19$13,889
Aripiprazole170$5,471
Lurasidone Hcl25$5,293
Paliperidone ErPaliperidone35$4,850
Clonazepam365$4,196
Alprazolam659$3,916
Duloxetine Hcl162$3,299
Quetiapine Fumarate197$3,163
Ziprasidone Hcl49$3,137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$41$113,62920 claims
Johnson & JohnsonRisperdal Consta, Spravato$44$49,72241 claims
Otsuka America Pharmaceutical, Inc.Rexulti$200$47,44728 claims
AbbVieVraylar$261$25,05018 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$44$13,88919 claims
Almatica Pharma LLCSertraline Hcl$24$1,171118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 565 psychiatric/mental health providers in Missouri.

Other psychiatric/mental health in Lees Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →